Vaccinex has been granted a patent for antibodies targeting human CCR8 to treat diseases. The patent covers specific amino acid sequences within the N-terminal extracellular domain of CCR8. GlobalData’s report on Vaccinex gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Vaccinex Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Vaccinex, Personalized cancer vaccines was a key innovation area identified from patents. Vaccinex's grant share as of February 2024 was 47%. Grant share is based on the ratio of number of grants to total number of patents.

Antibodies binding human ccr8 for treating diseases

Source: United States Patent and Trademark Office (USPTO). Credit: Vaccinex Inc

A recently granted patent (Publication Number: US11859000B2) discloses an antibody or antigen-binding portion that specifically binds to amino acids within the N-terminal extracellular domain of human CCR8. The antibody comprises various amino acid sequences for VH CDR1, VH CDR2, VH CDR3, VL CDR1, VL CDR2, and VL CDR3. The patent claims that the antibody is capable of enhancing an immune response to a tumor, reducing Treg cells, activating NK cells, binding to CCR8, inducing internalization of CCR8, and inducing antibody-dependent cellular cytotoxicity, among other functions.

Furthermore, the patent describes the antibody as a humanized or chimeric antibody, a single-chain variable fragment (scFv), a bispecific antibody, a bispecific T cell engager (BiTE), or a multispecific antibody. It also covers the use of the antibody in immunoconjugates, antibody-drug conjugates, chimeric antigen receptors (CARs), and T cell receptors (TCRs). Additionally, the patent includes claims for nucleic acid molecules encoding the antibody, pharmaceutical compositions containing the antibody, methods of treating tumors using the antibody, and afucosylated antibodies targeting CCR8. The detailed amino acid sequences provided in the patent aim to protect the specific binding properties and therapeutic applications of the disclosed antibody.

To know more about GlobalData’s detailed insights on Vaccinex, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies